AnnJi (7754.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 7754.TWO's market cap?

AnnJi (7754.TWO) has a market capitalization of approximately $5.98 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 7754.TWO pay a dividend?

No — AnnJi (7754.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 7754.TWO profitable?

AnnJi (7754.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

7754.TWO

AnnJi

TWO·Biotechnology · Healthcare

NT$59.20NT$0.30+0.51%

Market capNT$5.98B·Aug 26 6:41 AM UTC

Price Chart

NT$59.20+NT$0.30 (+0.51%)today

+22.57%CAGR +9.84%

Select date range

FromTo

Jun 25, 2024Jun 25, 2024 → Aug 26, 2026· 2.2 yrsAug 26, 2026

Key Metrics

7754.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$959.00K

Net Income−NT$405.97M

Net Margin−42,332.1%

Operating Cash Flow−NT$334.88M

Capital ExpendituresNT$3.07M

Free Cash Flow−NT$337.95M

Return on Equity−96.9%

Return on Invested Capital−36.9%

Net CashNT$413.96M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 7754.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 7754.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 7754.TWO and 80,000+ other tickers.

About AnnJi

Founded in 2014 and headquartered in Taipei, Taiwan, AnnJi Pharmaceutical Co., Ltd. specializes in the creation of innovative medicinal treatments. The company's research and development pipeline addresses neurological, dermatological, and inflammatory conditions. Among its key therapeutic candidates are AJ201, which is being developed for the neurodegenerative disorder spinal and bulbar muscular atrophy, and AJ202, targeting androgenetic alopecia. AnnJi also works on AJ302, a histone deacetylase 6 inhibitor aimed at preventing and treating chemotherapy-induced peripheral neuropathy, and…

CEO: Wenying Huang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 80
Website: www.ajpharm.com

Peers

Peers Tab

6838.TWO

Formosa Pharmaceuticals, Inc.

Cap

NT$3.8B

6657.TW

Energenesis Biomedical CO.,LTD.

Cap

NT$2.7B

6492.TWO

Senhwa Biosciences, Inc.

Cap

NT$3.2B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 7754.TWO

What does AnnJi do?: AnnJi (7754.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 7754.TWO's market cap?: AnnJi (7754.TWO) has a market capitalization of approximately $5.98 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 7754.TWO pay a dividend?: No — AnnJi (7754.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 7754.TWO profitable?: AnnJi (7754.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.